Meditatav Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 4 Year, 10 Days
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2022)
- Ebitda 235.46%
(FY 2022)
- Net Worth 68.08%
(FY 2022)
- Total Assets 149.90%
(FY 2022)
About Meditatav Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Purushottam Singh, Ashish Singh, and Gaurav Singh serve as directors at the Company.
- CIN/LLPIN
U24230UP2020PTC139877
- Company No.
139877
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Meditatav Pharma Private Limited offer?
Meditatav Pharma Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication.
Who are the key members and board of directors at Meditatav Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Purushottam Singh  | Director | 30-Dec-2020 | Current |
| Ashish Singh | Director | 30-Dec-2020 | Current |
| Gaurav Singh | Director | 30-Dec-2020 | Current |
Financial Performance of Meditatav Pharma.
Meditatav Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 68.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meditatav Pharma?
Unlock access to Meditatav Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Meditatav Pharma?
Meditatav Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meditatav Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meditatav Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
